Marín PJ

Language: Spanish
References: 66
Page: 281-286
PDF size: 218.10 Kb.

ABSTRACT

Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative motor neuron disease in adults. It is characterized by the progressive loss of motor neurons resulting in a complex clinical manifestation and finally, death. This review presents the most recent findings about this disease. Less than 10 % of patients are familial ALS, associated to several loci of different functions. From them, more than 20 % have mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1) enzyme. Neuronal inclusions and defects in protein folding are present in both forms of ALS. Aberrant accumulation of neurofilament, defects in axonal transport, neuronal oxidative imbalance and glutamate excitoxicity are some of the possible mechanisms involved in the disease pathogenesis. Riluzol, a glutamate inhibitor, is the only approved drug for ALS treatment, producing an increase of 3 months in survival. More than 30 clinic trials have been carried out to obtain new treatments for ALS, including antioxidants, glutamate inhibitors, immunomodulators and growth factors, all with failed results. Genetic therapy, interference RNA and stem cell therapy are currently in study. Probably, the right strategy to follow must be the simultaneous intervention in different molecular events to alter the disease progression.

REFERENCES

1. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 2005; 76: 1046 57.

2. Bruijn LI, et al. Pathways to hope. The state of research into amyotrophic lateral sclerosis (online). Available at: http://www.alsa.org/ research/white paper.cfm?CFID=2413422&CFTOKEN=35b61 c8abdb4f02c 83884973 188B 2E62 805A6813AF77DB23 . Accessed: Dec 20, 2008.

3. Rowland LP. What’s in A Name? Amyotrophic Lateral Sclerosis, Mo tor Neuron Disease and Allelic Heterogeneity. Ann Neurol 1998; 43: 691 4.

4. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031 41.

5. Nelson LM. Epidemiology of ALS. Clin Neurosci 1995; 3: 327 31.

6. Figlewicz DA, Orrell RW. The genetics of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 225 31.

7. Chio A. Risk factors in the early diagnosis of ALS: European epidemiological studies. Amyotroph Lat Scler and Other Mot Neuron Dis 2000; 1: S13 S18.

8. Rodríguez ALR y cols. Bases biológicas y patobiológicas humanas de la esclerosis lateral amiotrófica. Universitas Médica 2006; 47: 35 54.

9. Ince PG, Codd GA. Return of the cycad hypothesis: does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/ PDC) of Guam have new implications for global health? Neuropathol Appl Neurobiol 2005; 31: 345 53.

10. Andersen PM. The genetics of amyotrophic lateral sclerosis (ALS). Suppl Clin Neurophysiol 2004; 57: 211 27.

11. Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59 62.

12. Gros Louis F, et al. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta 2006; 1762: 956 72.

13. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6: 37 46.

14. Cozzolino M, et al. Amyotrophic lateral sclerosis: from current develoments in the laboratory to clinical implications. Antioxid and Redox Sign 2008; 10: 405 43.

15. Chen YZ, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004; 74: 1128 35.

16. Nishimura AL, et al. A mutation in the vesicle trafficking protein VAPB causes late onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75: 822 31.

17. Munch C, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 2005; 58: 777 80.

18. Greenway MJ, et al. ANG mutations segregate with familial and “sporadic” amyotrophic lateral sclerosis. Nat Genet 2006; 38: 411 13.

19. Greenway MJ, et al. A novel candidate region for ALS on chromosome 14q11.2. Neurology 2004; 63: 1936 8.

20. Lambrechts D, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383 94.

21. Veldink JH, et al. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology 2005; 65: 820 5.

22. Al Chalabi A, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157 64.

23. Tomkins J, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998; 9: 3967 70.

24. Parkinson N, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006; 67: 1074 7.

25. Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. J Clin Pathol Mol Pathol 2001; 54: 386 92.

26. Bruijn LI, et al. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann Rev Neurosc 2004; 27: 723.

27. Valentine JS, Hart PJ. Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003; 100: 3617 22.

28. Shibata N, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic late ral sclerosis patients. Brain Res 2001; 917: 97 104.

29. Bogdanov MB, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000; 29: 652 8.

30. Ferrante RJ, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064 74.

31. Beal MF, et al. Increased 3 nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 644 54.

32. Liu D, et al. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 1999; 13: 2318 28.

33. Bogdanov MB, et al. Elevated “hydroxyl radical” generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998; 71: 1321 4.

34. Ferrante RJ, et al. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci 2001; 17: 89 96.

35. Bergomi M, et al. Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population based case control study. Environ Res 2002; 89: 116 23.

36. Gabbianelli R, et al. Aberrant copper chemistry as a major mediator of oxidative stress in a human cellular model of amyotrophic lateral sclerosis. J Neurochem 1999; 73: 1175 80.

37. Hottinger AF, et al. The copper chelator d penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997; 9: 1548 51.

38. Rothstein JD, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18 25.

39. Maragakis NJ, et al. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 2004; 55: 469 77.

40. Lin CL, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589 602.

41. Rattray M, Bendotti C. Does excitotoxic cell death of motor neurons in ALS arise from glutamate transporter and glutamate receptor abnormalities? Exp Neurol 2006; 201: 15 23.

42. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 97 114.

43. Hesse M, et al. Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18. J Cell Sci 2001; 114: 2569 75.

44. Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci 1996; 19: 187 217.

45. Shea TB, Flanagan LA. Kinesin, dynein and neurofilament transport. Trends Neurosci 2001; 24: 644 8.

46. Shea TB, et al. Does neurofilament phosphorylation regulate axonal transport? Trends Neurosci 2003; 26: 397 400.

47. Tomkins J, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998; 9: 3967 70.

48. Figlewicz DA, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757 61.

49. Ackerley S, et al. Glutamate slows axonal transport of neurofilaments in transfected neurons. J Cell Biol 2000; 150: 165 76.

50. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS linked SOD1 mutants to motor neurons. Nat Neurosci 1999; 2: 50 6.

51. Beaulieu JM, et al. Late onset of motor neurons in mice overexpressing wild type peripherin. J Cell Biol 1999; 147: 531 44.

52. He CZ, Hays AP. Expression of peripherin in ubiquinated inclusions of amyotrophic lateral sclerosis. J Neurol Sci 2004; 217: 47 54.

53. Robertson J, et al. A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol 2003; 160: 939 49.

54. Gros Louis F, et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem 2004; 279: 45951 6.

55. Bensimon G, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585 91.

56. Lacomblez L, et al. Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425 31.

57. Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. Amyotroph Lat Scler 2008; 9: 131 40.

58. Ralph GS, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11: 429 33.

59. Raoul C, et al. Lentiviral mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005; 11: 423 8.

60. Guillot S, et al. Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1 (G93A) transgenic mice. Neurobiol Dis 2004; 16: 139 49.

61. Kaspar BK, et al. Retrograde viral delivery of IGF 1 prolongs survival in a mouse ALS model. Science 2003; 301: 839 42.

62. Chi L, et al. Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells 2006; 24: 34 43.

63. Garbuzova Davis S, et al. Positive effect of transplantation of hNT neurons (NTera 2/D1 cell line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol 2002; 174: 169 80.

64. Hemendinger R, et al. Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis. Exp Neurol 2005; 196: 235 43.

65. Garbuzova Davis S, et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res 2003; 12: 255 70.

66. Vincent AN, et al. Strategic approaches to developing drug treatments for ALS. Drug Discovery Today 2008; 13(1/2): 67 72.